Role of Serum Levels of Angiogenic Cytokines in Assessment of Angiogenesis After Stem Cell Therapy of Diabetic Patients With Critical Limb Ischemia
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10293639" target="_blank" >RIV/00216208:11110/14:10293639 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/68378041:_____/14:00439786 RIV/00023001:_____/14:00059107
Výsledek na webu
<a href="http://dx.doi.org/10.3727/096368913X674071" target="_blank" >http://dx.doi.org/10.3727/096368913X674071</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3727/096368913X674071" target="_blank" >10.3727/096368913X674071</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Role of Serum Levels of Angiogenic Cytokines in Assessment of Angiogenesis After Stem Cell Therapy of Diabetic Patients With Critical Limb Ischemia
Popis výsledku v původním jazyce
The release of proangiogenic cytokines into the circulation after stem cell (SC) therapy and compensatory increase of angiogenesis inhibitors may reflect local vasculogenesis but also can increase the risk of side effects. The aim of our study was to evaluate serum levels of angiogenic cytokines with regard to the assessment of local and systemic vasculogenesis in diabetic patients with no-option critical limb ischemia (NO-CLI). Twenty-five diabetic patients with NO-CLI I treated with SCs isolated frombone marrow or stimulated peripheral blood were included in the study. Serum levels of proangiogenic cytokines (VEGF, bFGF, Ang-1, PDGF-AA, and PDGF-BB) and an antiangiogenic cytokine (endostatin) were assessed 6 months after cell treatment, compared tobaseline values, and correlated with the number of injected CD34(+) cells. The clinical effect of SC therapy (assessed by changes in TcPO2) and potential systemic vasculogenesis (assessed by eye fundus examination) were evaluated after 6
Název v anglickém jazyce
Role of Serum Levels of Angiogenic Cytokines in Assessment of Angiogenesis After Stem Cell Therapy of Diabetic Patients With Critical Limb Ischemia
Popis výsledku anglicky
The release of proangiogenic cytokines into the circulation after stem cell (SC) therapy and compensatory increase of angiogenesis inhibitors may reflect local vasculogenesis but also can increase the risk of side effects. The aim of our study was to evaluate serum levels of angiogenic cytokines with regard to the assessment of local and systemic vasculogenesis in diabetic patients with no-option critical limb ischemia (NO-CLI). Twenty-five diabetic patients with NO-CLI I treated with SCs isolated frombone marrow or stimulated peripheral blood were included in the study. Serum levels of proangiogenic cytokines (VEGF, bFGF, Ang-1, PDGF-AA, and PDGF-BB) and an antiangiogenic cytokine (endostatin) were assessed 6 months after cell treatment, compared tobaseline values, and correlated with the number of injected CD34(+) cells. The clinical effect of SC therapy (assessed by changes in TcPO2) and potential systemic vasculogenesis (assessed by eye fundus examination) were evaluated after 6
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FJ - Chirurgie včetně transplantologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
S - Specificky vyzkum na vysokych skolach
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Cell Transplantation
ISSN
0963-6897
e-ISSN
—
Svazek periodika
23
Číslo periodika v rámci svazku
12
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
7
Strana od-do
1517-1523
Kód UT WoS článku
000346626300004
EID výsledku v databázi Scopus
—